Teva Pharmaceutical Industries reported Q3 2026 adjusted earnings per share of $0.86 on revenue of $4.4 billion, beating Wall Street estimates of $0.72 per share and $4.22 billion. Strong performance in branded drugs—including Austedo, Ajovy, and Uzedy—offset a 16% decline in generic drug sales, prompting Teva to raise its full-year 2026 revenue guidance to $16.7–$17 billion. CEO Richard Francis outlined further growth expectations for 2027 and 2028 supported by biosimilars and new drug launches.
Q3 2026 financial results and market reaction
- ▪Teva Pharmaceutical Industries generated $4.4 billion in Q3 2026 revenue, beating analyst expectations of $4.22 billion despite a 2% overall revenue decline.
- ▪Teva Pharmaceutical Industries' New York-listed shares rose 5.8% to $43 during morning trading on November 3, 2026 following its Q3 financial release.
- ▪Teva Pharmaceutical Industries reported adjusted earnings per share of 86 cents for Q3 2026, up from 78 cents per share in Q3 2025 and beating the LSEG analyst forecast of 72 cents per share.
Key branded drug sales performance
- ▪Teva Pharmaceutical Industries' migraine medication Ajovy reported $269 million in Q3 2026 revenue, a 61% increase, with full-year 2026 revenue projected at up to $960 million.
- ▪Teva Pharmaceutical Industries' Huntington's disease drug Austedo generated $751 million in Q3 2026 sales, a 21% increase, with full-year 2026 revenue expected to reach up to $2.65 billion.
- ▪Teva Pharmaceutical Industries' schizophrenia treatment Uzedy doubled its Q3 2026 revenue to $85 million, with full-year 2026 sales projected to reach approximately $300 million.
Generic drug sales performance and outlook
- ▪Teva Pharmaceutical Industries projects future generic division growth driven by the commercial launch of its biosimilar product pipeline.
- ▪Teva Pharmaceutical Industries' strong revenue from branded medicines compensated for quarterly sales declines in its generic pharmaceutical division during Q3 2026.
- ▪Teva Pharmaceutical Industries experienced a 16% decline in Q3 2026 generic drug sales, dragging overall quarterly revenue down 2% to $4.4 billion.
- ▪Teva Pharmaceutical Industries Chief Executive Officer Richard Francis stated that Teva has invested three and a half years of development into its generics biosimilar business.
Full-year 2026 and long-term outlook
- ▪Teva Pharmaceutical Industries Chief Executive Officer Richard Francis projected continued company revenue growth in 2027, led by its branded medicine portfolio.
- ▪Teva Pharmaceutical Industries anticipates significant revenue from schizophrenia drug Weltruza starting in the second half of 2027, with projected peak annual sales of up to $2 billion.
- ▪Teva Pharmaceutical Industries projected full-year 2026 adjusted earnings per share between $1.92 and $2.11.
- ▪Teva Pharmaceutical Industries raised its full-year 2026 revenue guidance to between $16.7 billion and $17 billion, citing higher sales projections for branded drugs Austedo, Ajovy, and Uzedy.
Story comments
Loading comments…